Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Go or no go? A delayed decision on Evrenzo
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
